Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling p...
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.